HOSPITAL UNIVERSITARIO RUBER

Departamento

Foto de HOSPITAL UNIVERSITARIO RUBER

Foto de National Cancer Center

National Cancer Center

Plainview, Estados Unidos

Publicaciones en colaboración con investigadores/as de National Cancer Center (5)

2020

Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
New England Journal of Medicine, Vol. 382, Núm. 7, pp. 610-621

2019

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
JAMA Oncology, Vol. 5, Núm. 11, pp. 1556-1563

2017

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
Breast Cancer Research and Treatment, Vol. 165, Núm. 3, pp. 601-609

2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

2015

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710